Welcome to Multibagg AI
Log in to access personalized features
Bearish
3
Neutral
5
Bullish
6
Bearish
35
Neutral
5
Bullish
6
Bearish
32
Neutral
0
Bullish
0
Board Meeting - Audited Results
Unjha Formulations Ltd will hold a board meeting on 18-May-2026 to consider and approve audited financial results as of 31/03/2026 and to appoint a secretarial auditor for FY2025-26.
Board Meeting - Audited Results
Unjha Formulations will hold a Board meeting on 18‑May‑2026 at 13:30 to consider and approve audited financial results for the period ended 31‑Mar‑2026 and to appoint a secretarial auditor for FY 2025‑26.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Unjha Formulations Ltd (UNJHAFOR) is currently trading at 19.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Unjha Formulations Ltd is a prominent manufacturer of pharmaceutical formulations including liquids, powders, tablets, capsules, and injectables. They are pioneers in Ayurvedic Isabgol products. The company operates two major divisions for human and veterinary products, making it one of the largest Isabgol product manufacturers in India. It possesses a state-of-the-art manufacturing facility certified with a GMP certificate, ensuring high-quality production standards. Unjha Formulations Ltd has successfully tapped into export markets, contributing to its growth, with a new direction in areas like Ferrous Sulphate and Iron Folic Tablets. A notable strategic move includes their manufacturing agreement with Nicholas Piramal India Ltd for Fybogel, indicating strategic partnership capabilities.
Over the past 52 weeks, Unjha Formulations Ltd has traded between a low of ₹18.99 and a high of ₹30.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Unjha Formulations Ltd has a market capitalization of approximately 9.39. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Unjha Formulations Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 8.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 9.39 Cr, Unjha Formulations Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Unjha Formulations Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Unjha Formulations Ltd is 8.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Upcoming Result Date: May 17, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
15.00 | 12 Cr | -13.51 | 9.52 | 0.00 | -73.01 | -42.20 | -23.24 | ||
21.50 | 12 Cr | 716.67 | 1.23 | 0.00 | 2.47 | 7.06 | 0.06 | ||
31.18 | 12 Cr | -2.30 | 0.00 | 0.00 | 75.76 | -46.38 | -28.70 | ||
20.24 | 9 Cr | 8.61 | 2.16 | 0.00 | 23.59 | 26.37 | 16.12 | ||
7.50 | 8 Cr | -0.94 | 0.43 | 0.00 | -42.34 | -50.18 | -33.92 | ||
2.05 | 8 Cr | -51.25 | 1.72 | 0.00 | -6.62 | -0.04 | -0.30 | ||
12.00 | 7 Cr | 100.00 | 0.89 | 0.00 | 0.96 | 2.20 | 0.79 | ||
| Median: 7 Co. | — | 15.00 | 9 Cr | -0.94 | 1.23 | 0.00 | 0.96 | -0.04 | -0.30 |
Unjha Formulations Ltd is a prominent manufacturer of pharmaceutical formulations including liquids, powders, tablets, capsules, and injectables. They are pioneers in Ayurvedic Isabgol products.
The company operates two major divisions for human and veterinary products, making it one of the largest Isabgol product manufacturers in India.
It possesses a state-of-the-art manufacturing facility certified with a GMP certificate, ensuring high-quality production standards.
Unjha Formulations Ltd has successfully tapped into export markets, contributing to its growth, with a new direction in areas like Ferrous Sulphate and Iron Folic Tablets.
A notable strategic move includes their manufacturing agreement with Nicholas Piramal India Ltd for Fybogel, indicating strategic partnership capabilities.
Pharmaceuticals & Biotechnology
Pharmaceuticals
9 Cr
Low Risk
8.6
33.1
0.5
2.2
30.40
18.99
Sales CAGR
Profit CAGR
ROE
ROCE
